Jae B. Kim Form 3 Design Therapeutics / Jae B. Kim ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Kim Jae B.

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CA 92011

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/13/2024

3. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,756	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	01/31/2032	Common Stock	315,000	12.77	D
Stock Option (right to buy)	(2)	01/31/2033	Common Stock	115,000	7.97	D
Stock Option (right to buy)	(3)	01/01/2034	Common Stock	175,000	2.54	D

Explanation of Responses:

1. The shares subject to the option will vest as follows: 25% of the shares vested on January 24, 2023, and the balance will vest in equal monthly installments thereafter over a three year period.

2. The shares subject to the option will vest as follows: 20% of the shares vested on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.

3. The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2025, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.

	/s/ Mustapha Parekh, Attorney-in-Fact	03/20/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.